As of November 7, 2025
We will taken on the challenge of “drug discovery innovation” to create new value by combining drug discovery technologies and disease research.
And also, we will expand target modalities and disease fields and pursue in-licensing initiatives in a wide range of areas to broaden our development pipeline, and proactive partnering activities.
Ph3 ～ Application submitted
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅢ(Sep 2022) | KRP-R120 / Interstitial lung disease: ILD (pulmonary sarcoidosis) |
aTyr pharma | It is a fusion protein drug having the action to suppress, by binding to neuropilin-2 (NRP2) receptor, the excessive activation of immune cells, and is a potential first-in-class therapy to treat inflammatory diseases such as pulmonary sarcoidosis. |
POC Project (PhⅠ ～ PhⅡ)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅠ(Aug 2022) | KRP-114VP / Overactive bladder | Merck | Additional Indication for Beova in pediatric patients. |
Licensing development (License-in)
| Stage | Compound / Code | Origin | Features |
|---|---|---|---|
| PhⅠ Bayer |
KRP-S124 (BAY2925976) / OSA |
Bayer | BAY2925976 works as an ADRA2C antagonist, helping to centrally reduce upper airway collapse. It is expected to improve the temporary apneas and hypopneas commonly observed in patients with OSA. License agreement to obtained the exclusive worldwide rights to manufacture, develop, and commercialize BAY2925976 and its backup compound.(Dec 2024) |
| PhⅠ in preparation Hinge Bio, Inc. |
KRP-A225 (HB2198) / Systemic Lupus Erythematosus (SLE) etc. |
Hinge Bio, Inc. | A bispecific antibody targeting CD19 and CD20 on the surface of B cells. Expected to provide therapeutic benefit for SLE by "reset” the immune system through B cell depletion. Enter into a Collaboration and License Agreement ofHB2198 in Japan for SLE and other diseases (September 2025) |
Licensing development (License-out)
| Stage/Overseas | Compound / Code | Licensee | Origin | Features |
|---|---|---|---|---|
| PhⅢ | KRP-203 | Priothera | In-house | Sphingosine-1-Phosphate Receptor Agonist. |
| preclinical | KRP-M223 | Novartis | In-house | MRGPRX2 antagonist. |
DTx
| Origin | Code | Proposed Indication | Note |
|---|---|---|---|
| SUSMED | KRP-DT123 | Tinnitus | Collaboration research and sales agreement for development of Digital Therapeutics (DTx) in otolaryngology Field (Nov 2022) Specified clinical trial is in progress. |
| Hyfe | KRP-DC125 | Chronic Cough | Development and commercialization agreement for DTx for chronic cough. |
Option Agreement
| Stage | Code / Target | Origin | Features |
|---|---|---|---|
| PhⅠ Biodol |
BDT272 / Chronic pain etc |
Biodol | BDT272 is anticipated to demonstrate effective analgesic properties through the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of chronic pain condition such as neuropathic pain. Option agreement to obtain an option for the license of the right to develop and commercialize BDT272 in Japan and other territories in Asia (excluding China) (Jan 2025) |
| PhⅡ Cyrano |
CYR-064 / Post viral loss of smell |
Cyrano | CYR-064, phosphodiesterase inhibitor (PDEi) theophylline, targets the inhibition of cAMP degradation thereby increasing intracellular concentrations and increasing olfactory neuron excitability. |